BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22970187)

  • 1. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
    Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
    PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
    Zhang MY; Vu BK; Choudhary A; Lu H; Humbert M; Ong H; Alam M; Ruprecht RM; Quinnan G; Jiang S; Montefiori DC; Mascola JR; Broder CC; Haynes BF; Dimitrov DS
    J Virol; 2008 Jul; 82(14):6869-79. PubMed ID: 18480433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
    Alsahafi N; Debbeche O; Sodroski J; Finzi A
    PLoS One; 2015; 10(4):e0122111. PubMed ID: 25849367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
    Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
    PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.
    Chakrabarti BK; Walker LM; Guenaga JF; Ghobbeh A; Poignard P; Burton DR; Wyatt RT
    J Virol; 2011 Aug; 85(16):8217-26. PubMed ID: 21653673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units.
    Löving R; Sjöberg M; Wu SR; Binley JM; Garoff H
    J Virol; 2013 Jun; 87(12):7000-7. PubMed ID: 23596290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
    Yasmeen A; Ringe R; Derking R; Cupo A; Julien JP; Burton DR; Ward AB; Wilson IA; Sanders RW; Moore JP; Klasse PJ
    Retrovirology; 2014 May; 11():41. PubMed ID: 24884783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.
    Kumar R; Ozorowski G; Kumar V; Holden LG; Shrivastava T; Patil S; Deshpande S; Ward AB; Bhattacharya J
    J Biol Chem; 2017 Sep; 292(38):15849-15858. PubMed ID: 28743743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.
    Qiao ZS; Kim M; Reinhold B; Montefiori D; Wang JH; Reinherz EL
    J Biol Chem; 2005 Jun; 280(24):23138-46. PubMed ID: 15833740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
    Sanders RW; Derking R; Cupo A; Julien JP; Yasmeen A; de Val N; Kim HJ; Blattner C; de la Peña AT; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; van Gils MJ; King CR; Wilson IA; Ward AB; Klasse PJ; Moore JP
    PLoS Pathog; 2013 Sep; 9(9):e1003618. PubMed ID: 24068931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
    Huang J; Kang BH; Pancera M; Lee JH; Tong T; Feng Y; Imamichi H; Georgiev IS; Chuang GY; Druz A; Doria-Rose NA; Laub L; Sliepen K; van Gils MJ; de la Peña AT; Derking R; Klasse PJ; Migueles SA; Bailer RT; Alam M; Pugach P; Haynes BF; Wyatt RT; Sanders RW; Binley JM; Ward AB; Mascola JR; Kwong PD; Connors M
    Nature; 2014 Nov; 515(7525):138-42. PubMed ID: 25186731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.